Data to be presented on ABBV-514, a novel CCR8 targeting antibody, in Phase 1 for non-small cell lung cancer, head and neck cancer and other solid tumors. Other presentations highlight key ...

cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster ...